Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;10(4):401-10.
doi: 10.1007/s11897-013-0155-7.

The emerging epidemic of heart failure with preserved ejection fraction

Review

The emerging epidemic of heart failure with preserved ejection fraction

A Afşin Oktay et al. Curr Heart Fail Rep. 2013 Dec.

Abstract

Heart failure with preserved ejection fraction (HFpEF), which currently represents approximately 50 % of heart failure (HF) cases, is common and associated with high morbidity and mortality. Understanding the epidemiology of HFpEF has been difficult due to the challenges in HFpEF diagnosis and the heterogeneous etiologies and pathophysiologies that underlie HFpEF. Nevertheless, several high-quality epidemiology and observational registry studies of HFpEF demonstrate that an increasing prevalence of HFpEF in both the outpatient and inpatient settings, coupled with a lack of evidence-based effective treatments for HFpEF, is resulting in an emerging epidemic of HFpEF. In this review, we discuss the emerging HFpEF epidemic, focusing on: (1) reasons for the rising prevalence of HFpEF; (2) the abnormalities in cardiac structure and function that dictate the transition from risk factors to HFpEF; (3) novel HFpEF mechanisms that may underlie the increase in HFpEF prevalence; (4) prognosis of HFpEF; and (5) risk prediction in HFpEF. We conclude with 10 unanswered questions onHFpEF epidemiology thatwill be important areas for future investigation.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethics Guidelines

Conflict of Interest A. Afşin Oktay declares that he has no conflict of interest.

Jonathan D. Rich has received honoraria from Thoratec for consulting services.

Sanjiv J. Shah is supported by grants from the American Heart Association (#0835488 N) and National Institutes of Health (R01 HL107557); has received a research grant from Gilead Sciences; has received compensation for serving as a consultant for Novartis, Bayer-Schering Pharma, and has received honoraria from the Pulmonary Hypertension Association.

Figures

Fig. 1
Fig. 1
The Changing Landscape of Heart Failure: The Projected Trajectory of HFpEF in Hospitalized Heart Failure Patients. Based on results from Get With the Guidelines-Heart Failure (GWTG-HF) Study (Steinberg et al. [11••]; N=110,621), using actual data on the proportion of hospitalization patients with three types of HF (HFpEF [EF>50 %]; HFrEF [EF<40 %]; and HF borderline-EF [EF 40–50 %]) at each time point between 2005–2010. The trajectories for 2011–2020 were estimated for HFpEF and HFrEF using linear regression analyses, while HF borderline-EF was held at a constant 14 % proportion of hospitalized HF patients. The regression equation for the projected HFpEF trajectory=−0.86(Year)+1771 (P=0.015 for the trend of decreasing HFrEF over time); the equation for the projected HFrEF trajectory= 1.086(Year)-2144 (P=0.008 for the trend of increasing HFpEF over time).

References

    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9. - PubMed
    1. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9. - PubMed
    1. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–77. - PubMed
    1. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, et al. Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2012;6(2):184–92. This study is the largest study known so far to have documented quality of life in HFpEF and found that quality of life of HFpEF is very poor, comparable to patients with end-stage renal disease. - PMC - PubMed
    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. - PMC - PubMed

Publication types